Press Release / Media Release
Zydus receives final approval from the USFDA for Tiadylt ER Capsules and Azelastine Hydrochloride Nasal Spray16-08-2017
16-08-2017
Company news
Cadila Healthcare on Monday said patent litigation relating to Aptalis' drug Canasa used for treatment of ulcerative colitis has been settled. As a result of the settlement, the company's US...14-08-2017
Press Release / Media Release
Zydus announces settlement with Aptalis on CANASA (mesalamine suppository, 1 g)14-08-2017
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here13-08-2017
Updates
Voting Results of the 22nd Annual General Meeting of the Company held on August 11, 2017 as per Regulation 44 of the SEBI LODR.12-08-2017
Press Release / Media Release
Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use.11-08-2017
Cadila Healthcare Q1 profit falls 65% to Rs138 crore
Cadila Healthcare reported a 65.26% decline in its consolidated net profit at Rs138.4 crore for the first quarter ended June 3011-08-2017